drugset / Trial / NCT01072591

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

NCT01072591 ↗

Phase 1 Terminated 108 enrolled AstraZeneca MedImmune LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MEDI-578, a monoclonal antibody, in patients with osteoarthritis of the knee. It will also be evaluated how MEDI-578 is absorbed and distributed through the body.

Timeline

Start
2010-02
Primary completion
2010-09
Completion
2010-09

Outcome

Outcome not reported

Stopped: “Amended clinical development plan.”

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI-578 Monoclonal antibody — Intravenous

Indications